Anivive Lifesciences Inc.
Long Beach, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 3777 Worsham Ave #200, Long Beach, CA 90808, USA
- Website
- anivive.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $4,889,710 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| BAA research area 001 - development of vaccine candidates for biodefense and emerging infectious diseases | National Institute of Allergy and Infectious Diseases (NIH) | $4,889,710 |
Grant awards
Similar vendors
About the company
Anivive Lifesciences Inc. is a self-certified small disadvantaged business and for-profit organization that provides research and development services to the federal government, particularly in the areas of vaccine development and veterinary medicine. Registered in SAM.gov since December 2019, the company has received both federal contract and grant awards. Anivive Lifesciences Inc. appears to specialize in developing innovative solutions for animal health and biodefense, working on projects that span from vaccine candidates for emerging infectious diseases to treatments for canine lymphoma.
In June 2024, Anivive Lifesciences Inc. was awarded a significant federal contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This $33,273,522 cost-plus-fixed-fee definitive contract is focused on the development of vaccine candidates for biodefense and emerging infectious diseases. The contract, which is set to run until June 2026, is part of NIAID's Broad Agency Announcement (BAA) research program. The primary objective is to advance the research and development of promising vaccine candidates capable of providing rapid and durable immunity against multiple emerging pathogens. This contract was not set aside for any specific type of business, indicating that Anivive Lifesciences Inc. competed successfully in an open market procurement.
Anivive Lifesciences Inc. has also received federal grant awards from the Center for Veterinary Medicine, demonstrating its involvement in animal health research. In December 2022, the company was awarded a project grant (R01FD007800) to develop an additional strength of Laverdia tablets, a veterinary medication. This grant, running until November 2023, aims to add a 22.5 mg tablet to the existing portfolio of 2.5 mg, 10 mg, and 50 mg tablets, utilizing approved analytical procedures for assessment and testing. Previously, in June 2020, Anivive Lifesciences Inc. received another project grant (R01FD006919) for a multi-center pivotal field study to confirm the effectiveness and safety of Verdinexor for the treatment of lymphoma in dogs. This grant had a duration of three years, ending in May 2023. These grants highlight Anivive Lifesciences Inc.'s commitment to advancing veterinary medicine and developing innovative treatments for animal health conditions.
Quick answers
Is Anivive Lifesciences Inc. registered in SAM.gov?
Yes. Anivive Lifesciences Inc.'s SAM.gov registration is active through September 17, 2027.
What is Anivive Lifesciences Inc.'s CAGE code?
Anivive Lifesciences Inc.'s CAGE code is 8G6Z6, and its Unique Entity ID (UEI) is HR9KVMTD5467.
How much has Anivive Lifesciences Inc. received in federal contracts?
Federal contracts obligated $4,889,710 to Anivive Lifesciences Inc. in fiscal years 2023 through 2027.
What is Anivive Lifesciences Inc.'s most recent federal award?
Anivive Lifesciences Inc.'s most recent federal contract award is BAA research area 001 - development of vaccine candidates for biodefense and emerging infectious diseases (75N93024C00009), from National Institute of Allergy and Infectious Diseases (NIH), on June 7, 2024.
On GovTribe
See Anivive Lifesciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors